Tonix Pharmaceuticals (NASDAQ:TNXP) Stock Price Down 2.5% - Should You Sell?

Shares of Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP - Get Free Report) fell 2.5% on Monday . The stock traded as low as $33.20 and last traded at $34.60. 232,175 shares changed hands during mid-day trading, a decline of 76% from the average session volume of 957,680 shares. The stock had previously closed at $35.48.

Analyst Ratings Changes

A number of brokerages recently commented on TNXP. Alliance Global Partners restated a "buy" rating on shares of Tonix Pharmaceuticals in a report on Tuesday, June 3rd. Noble Financial restated an "outperform" rating and set a $70.00 target price on shares of Tonix Pharmaceuticals in a report on Thursday, March 20th. Finally, Wall Street Zen upgraded Tonix Pharmaceuticals from a "sell" rating to a "hold" rating in a report on Saturday, June 7th.

Tonix Pharmaceuticals Stock Down 0.1%

The company has a market cap of $260.84 million, a P/E ratio of -0.02 and a beta of 2.05. The business has a fifty day moving average of $30.90 and a 200 day moving average of $24.39.

Tonix Pharmaceuticals (NASDAQ:TNXP - Get Free Report) last posted its quarterly earnings data on Monday, May 12th. The company reported ($2.84) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($3.23) by $0.39. The business had revenue of $2.43 million during the quarter, compared to the consensus estimate of $2.55 million. Tonix Pharmaceuticals had a negative return on equity of 120.96% and a negative net margin of 1,313.87%. On average, sell-side analysts anticipate that Tonix Pharmaceuticals Holding Corp. will post -1762.5 EPS for the current fiscal year.

Insider Transactions at Tonix Pharmaceuticals

In other news, CEO Seth Lederman acquired 4,000 shares of the firm's stock in a transaction on Thursday, May 15th. The stock was acquired at an average price of $21.55 per share, for a total transaction of $86,200.00. Following the completion of the acquisition, the chief executive officer owned 4,005 shares in the company, valued at $86,307.75. This trade represents a 80,000.00% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 0.03% of the company's stock.

Institutional Trading of Tonix Pharmaceuticals

A number of hedge funds have recently made changes to their positions in TNXP. Commonwealth Equity Services LLC purchased a new position in Tonix Pharmaceuticals during the fourth quarter valued at $40,000. Two Sigma Investments LP bought a new position in shares of Tonix Pharmaceuticals during the fourth quarter valued at $66,000. Northern Trust Corp purchased a new position in shares of Tonix Pharmaceuticals in the 4th quarter worth about $162,000. IFP Advisors Inc bought a new position in Tonix Pharmaceuticals in the 1st quarter worth about $179,000. Finally, Rhumbline Advisers purchased a new stake in Tonix Pharmaceuticals during the 1st quarter valued at about $244,000. 82.26% of the stock is owned by institutional investors.

About Tonix Pharmaceuticals

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.